Libtayo's FDA approval offers an effective adjuvant option for high-risk cutaneous squamous cell carcinoma, reducing recurrence risk by 68% in the C-POST trial. Administered post-surgery and radiation ...
There are three common types of skin cancer in the United States: basal cell carcinoma, squamous cell carcinoma and melanoma. Merkel cell carcinoma is a rare type of skin cancer. Fred Hutch Cancer ...
Libtayo is approved for adjuvant treatment in high-risk CSCC patients post-surgery and radiation, showing significant disease-free survival benefits in the C-POST trial. The C-POST trial excluded ...
Basal cell carcinoma often appears as a shiny bump or red patch on sun-exposed skin. Aside from appearance, some skin cancers may feel tender, itchy, or painful, or may bleed. Early detection of skin ...
A phase 2 study of first-line (1L) domvanalimab (dom), zimberelimab (zim), and chemotherapy (chemo) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): ...
Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC) ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Samuel J. Klempner ...
The best way to detect skin cancer is to know what skin cancer looks like, do monthly self-exams and have regular exams by your health care provider to check for abnormalities that could be cancerous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results